Graduate Information
As a part time, distance learning course, the MSc in Precision Cancer Medicine welcomes a global cohort each year. In 2023 and 2024, students from 17 countries were enrolled in the course.

The MSc is designed for professionals from a variety of backgrounds with an interest in genomics and precision medicine in cancer. The course will appeal to practicing clinicians and pharmacists at all stages of their career, and academics and industry staff from medical specialists to practitioners in health economics, ethics, bio-informatics and biology.
"What I enjoyed most was the intellectual diversity and international perspective fostered by the program. Collaborative learning with peers from different healthcare systems and specialties expanded my horizons and helped me contextualize my own understanding of cancer medicine." - Sudha Surisetti, MSc Precision Cancer Medicine 23-25


"The course accommodates professionals from different areas, for example, geneticists, data scientists, pharmacists, physicians and surgeons, with a common goal of enhancing their knowledge and skills in precision cancer medicine. Interacting with course colleagues gave me the opportunity to develop a wide professional network." - Ee Phui Kew, MSc Precision Cancer Medicine 22-24
Hear from our graduates
Jakub Hantabal completed his master's in Precision Cancer Medicine in 2024 and is now a doctoral student at the Pandemic Sciences Institute at the University of Oxford, working on characterising the host-pathogen interactions of henipaviruses in the context of pandemic preparedness. Jakub was drawn to the flexible nature of the course which enabled him to continue running his consultancy business alongside his studies. In this interview, Jakub discusses his experience as a master's student and how it helped prepare him to undertake a DPhil.
Sudha Surisetti, a senior anatomic and molecular pathologist from India, studied the MSc in Precision Cancer Medicine to gain a holistic understanding of this fast evolving field. Sudha shares her experience of studying a remote, part-time course at Oxford, collaborating with a dynamic international peer group, and learning learn from experts within the Department of Oncology, renowned for its translational research focus.
How Oxford’s MSc in Precision Cancer Medicine Transformed My Professional Practice
For Senior Research Technician Erin Jarvis, the flexibility of the course offered the perfect opportunity to enhance her knowledge and skills, while continuing her work in the lab. Studying the MSc in Precision Cancer Medicine reignited her passion for academia and inspired her to pursue a PhD.
From MSc to PhD: Erin's Journey in Precision Cancer Medicine
Ee Phui Kew, MBBS, is a cardiothoracic surgeon, with a specific interest in thoracic oncology. He undertook the MSc in Precision Cancer Medicine course in 2022-2024 to equip himself with essential knowledge in precision cancer medicine that is changing the landscape of cancer diagnosis and treatment.
MSc Precision Cancer Medicine: A Surgeon's Experience
Sergey Dyshlovoy, Priv.-Doz., PhD, DSc, undertook the MSc in Precision Cancer Medicine in 2022-2024, alongside his full time role as a postdoctoral researcher at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany. The knowledge and skills he learned during his studies have inspired him to plan new projects in his lab.
Wen Yuen Lim, MPharm, applied to study MSc Precision Cancer Medicine while working as a pharmacist prescriber in chronic lymphocytic leukaemia, wanting to update her knowledge in the ever-changing field of cancer medicine. During her studies, Yen gained knowledge and skills applicable to her daily pharmacy practice and discovered research interests she will continue to pursue in her career.
Studying MSc Precision Cancer Medicine as a Haematology Pharmacist
Student Publications
Students will take on dissertation projects during Year 2, receiving supervision from world-leading experts in genomics and precision cancer in oncology. Several past students were able to formally publish their work in peer-reviewed journals:
A Rachel Moore, et al. Use of genome sequencing to hunt for cryptic second-hit variants: analysis of 31 cases recruited to the 100 000 Genomes Project. J Med Genet. Nov 2023;60(12):1235-1244.
Brian Lam, et al. Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review. Cancers (Basel). Feb 2023;15(4):1164.